Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PYXS has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
PYXS stock price ended at $1.14 on Wednesday, after losing-4.2%
The Pyxis Oncology Inc stock price decreased by -4.2% on the last trading day (18 Jun 2025), dropping from 1.2 to 1.14. Throughout the last trading session, the stock experienced a fluctuation of 7.05% , ranging from a day low of $1.135 to a day high of 1.215. The price has declined in 7 of the last 10 days, resulting in a total change of -10.94% during this period. On the last day, trading volume increase by 221.38K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 485.58K shares were traded, amounting to approximately 565.50K.
PYXS Technical Signals
PYXS(Pyxis Oncology Inc Corp) has 7 buy signals and 2 sell signals now. The current trend is downtrend starting from 2025-06-10. The total price change during this trend is -14.93%. Recently, the price has decreased with an increase in volume, indicating a strong bearish signal. The average turnover of PYXS over the last 5 trading days is 453.28K. Overall, the technical indicator signals lean more toward a Bullish outlook in the mid-term.
PYXS Moving Average Analysis
Pyxis Oncology Inc's overall moving average trend leans more bearish as of Friday, June 20, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $1.4356166666666663, and $1.5406666666666664. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $1.0957166666666667, and $0.9906666666666666. A break-down below any of these levels will issue sell signals.
PYXS Short Selling Analysis
The short sale ratio of Pyxis Oncology Inc(PYXS) as of 17 Jun 2025 is 37.07%, rising from last trading day. With increasing price from 1.21 to 1.19. The short sell activity indicate that short sellers may be anticipating further declines.
Technical Signal
Technical Signals Summary
Sell
2
Buy
7
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
7 Bullish Signals
7 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
6.414
Bullish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-115.939
Bullish
Awesome Oscillator (5, 34)
AO_5_34 > 0
0.00532
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.0135
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
2.117
Bullish
Williams %R (14 days)
WILLR_14 < -80
-98.182
Bullish
Ultimate Oscillator (7, 14, 28)
UO_7_14_28 < 30
26.702
Bullish
2 Bearish Signals
2 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Momentum (10 days)
MOM_10 < 0
-0.14
Bearish
Closing price
close < fibonacci_S1
1.14
Bearish
PYXS Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Pyxis Oncology Inc(PYXS), our algorithm predicts PYXS's 1-month price at $1.52, with an 26.27%upwardshift. Using a similarity score up to 91.00%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Pyxis Oncology Inc (PYXS.O) stock, as of Sunday, June 15, 2025 , forecasts a 26.27% change over the next month, based on its high correlation with MBIN.O stock patterns. The similarity between their price movements over the analyzed periods is 91%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
PYXS
No Data
MBIN
Up: 26.27%Similarity: 91%
Name
Similarity
Up/Down
MBIN.O
91.00%
+26.27%
CDXS.O
90.85%
+0.31%
NI.N
90.42%
+2.69%
MCY.N
90.33%
-1.21%
CNS.N
90.14%
-0.38%
DMLP.O
90.12%
+2.87%
SAR.N
90.05%
+3.07%
PYXS Seasonality Analysis
Based on PYXS's historical stock price data across all years, the probability of a positive return in June is0.00%, suggesting it maynotbe an ideal month to invest in PYXS. In contrast,Julyoffers the highest probability of positive returns at100.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Pyxis Oncology Inc (PYXS.O) stock in July has the highest probability of a positive return (100.00%), while June has the lowest probability (0.00%).
Performance Seasonality
The chart shows Pyxis Oncology Inc. (PYXS)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Pyxis Oncology Inc (PYXS.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. PYXS has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Pyxis Oncology Inc (PYXS.O) stock in a year?
The radar chart shows that buying Pyxis Oncology Inc (PYXS.O) stock in July has the highest probability of a positive return (100.00%), while June has the lowest probability (0.00%).
How has Pyxis Oncology Inc. (PYXS)'s stock price performed over the past three years?
PYXS's stock price rose by 30.43% in 2023,decreased by -24.27% in 2024, and went down by 32.54% in 2025.
Bearish technical signals of PYXS include: MOM_10 < 0, close < fibonacci_S1.
Is PYXS a buy based on overall technical signals summary?
PYXS has 7 buy signals and 2 sell signals now. Overall the technical rating for PYXS is Strong buy . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of PYXS.
What is the trend of Pyxis Oncology Inc (PYXS)'s moving average?
Pyxis Oncology Inc's overall moving average trend leans more bearish as of June 20 2025, with 3 negative signals and 1 positive signal.
What is price prediction for PYXS stock next month?
The price prediction chart for Pyxis Oncology Inc (PYXS.O) stock, as of June 15 2025, forecasts a 26.27% change over the next month, based on its high correlation with MBIN stock patterns. The similarity between their price movements over the analyzed periods is 91%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for PYXS Stock?
The price prediction for PYXS stock in 2025 is $1.50, driven by FDA Fast Track Designation for its lead candidate and a 2.7-year cash runway. However, risks include high cash burn and mixed analyst sentiments, with potential upside to $5 if positive catalysts emerge.
What is price prediction 2030 for PYXS Stock?
### **Price Prediction for PYXS Stock in 2030**
Based on current trends and analysis, PYXS stock is predicted to reach **$8.00** by 2030. This forecast is supported by the company's promising clinical pipeline, including the FDA Fast Track Designation for PYX-201, and its cash runway of 2.7 years, which provides stability for ongoing research and development. However, risks such as high cash burn relative to market capitalization and reliance on clinical trial outcomes could impact the stock's performance.